Skip to main content
新赣江 logo

新赣江 — Investor Relations & Filings

Ticker · 920367 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 389 across all filing types
Latest filing 2025-10-29 Interim / Quarterly Rep…
Country CN China
Listing Beijing Stock Exchange 920367

About 新赣江

http://www.xgjyy.com/

Jiangxi Xinganjiang Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company's portfolio encompasses chemical active pharmaceutical ingredients (APIs), chemical drug preparations, and traditional Chinese medicine (TCM) formulations. Its core product offerings target therapeutic areas such as cardiovascular and cerebrovascular health, digestive system disorders, and nutritional supplementation. Key products include Ginkgo Biloba extract, Vitamin C, and various gastrointestinal medications. By maintaining an integrated value chain that spans from raw material synthesis to finished dosage forms, the company ensures quality control and supply chain efficiency. It focuses on delivering high-quality healthcare solutions through continuous innovation in pharmaceutical manufacturing and formulation technology.

Recent filings

Filing Released Lang Actions
2025年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "江西新赣江药业股份有限公司 2025 年第三季度报告" which translates to "Jiangxi New Ganjiang Pharmaceutical Co., Ltd. 2025 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial changes for the period ending September 30, 2025. The document explicitly states it is a quarterly report (第三季度报告) and includes comprehensive financial statements and management commentary. It also mentions that the report is unaudited, which is typical for interim or quarterly reports. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is not merely an announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2025
2025-10-29 Chinese
为全资子公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the provision of a guarantee by the parent company for its wholly-owned subsidiary's loan. It details the guarantee amount, decision-making process, risk assessment, and compliance with regulatory requirements. It includes board meeting resolutions and opinions from the sponsoring institution. The document is relatively short (2913 characters) and focuses on a specific financing guarantee event rather than comprehensive financial data or a full report. It does not contain financial statements or detailed financial analysis. Therefore, it is best classified as a Capital/Financing Update (CAP) since it relates to financing activities and guarantees provided by the company.
2025-10-29 Chinese
第三届董事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 13th meeting of the 3rd Board of Directors of Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It includes details about the meeting date, attendance, and voting results on several agenda items such as approval of the 2025 Q3 report, reappointment of the audit firm, provision of guarantees for a subsidiary, and scheduling a shareholders' meeting. The document references other filings where the actual reports and announcements are published (e.g., the 2025 Q3 report, audit firm appointment, guarantee announcement). The document itself does not contain the full quarterly report or financial statements but is a board meeting resolution announcement. This fits the category of Board/Management Information (MANG), which covers announcements of board decisions and management changes or approvals. The document length is short (2316 characters), and it is not the report itself but an announcement of board resolutions related to various corporate matters.
2025-10-29 Chinese
拟续聘2025年度会计师事务所公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the proposed reappointment of an accounting firm (audit firm) for the fiscal year 2025. It details the background, qualifications, and independence of the audit firm, the audit fees, and the approval process by the board and audit committee. It does not contain any actual audit report or financial statements, but rather is a notice about the appointment of the auditor. This fits the category of Audit Report / Information (AR), which includes standalone audit reports and related information about audit firms and their engagement, excluding full annual reports. The document is not a full annual report (10-K), nor is it a regulatory filing or report publication announcement. Therefore, the best classification is AR with high confidence. FY 2025
2025-10-29 Chinese
关于召开2025年第三次临时股东会通知公告（提供网络投票）
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice announcing the convening of the 2025 third extraordinary general meeting of shareholders (临时股东会通知公告) for Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It details the meeting date, voting methods (including online voting), eligibility, agenda items, and procedural instructions. It does not contain financial statements, audit reports, or detailed financial data. It is a formal announcement about the meeting itself, not the meeting materials or results. The document length is 2632 characters, which is relatively short and consistent with a meeting notice. Therefore, this document fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2025-10-29 Chinese
股东拟减持股份的预披露公告
Major Shareholding Notification Classification · 100% confidence The document is a pre-disclosure announcement regarding shareholders' planned reduction of their shareholdings. It details the shareholders involved, their current holdings, planned reduction quantities, methods, periods, and compliance with relevant laws and regulations. It also includes risk warnings related to the share reduction plan. There is no financial data, earnings information, or report publication mentioned. The document is a regulatory announcement about insider shareholding changes, specifically about planned share disposals by significant shareholders and insiders. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels or intentions to reduce holdings.
2025-10-29 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.